Anatara Lifesciences (ASX:ANR) "The Health Kick" podcast with Tim Boreham
Anatara Lifesciences CEO Steve Lydeamore sat down with Tim Boreham this week for Stockhead's new podcast series, "The Health Kick".
Anatara Lifesciences CEO Steve Lydeamore sat down with Tim Boreham this week for Stockhead's new podcast series, "The Health Kick".
Forecast expenditure for the December 2019 quarter is anticipated to increase as the Company advances the development of its Gastrointestinal Reprogramming (GaRP) dietary supplement. A refund from the Australian Taxation Office under the Federal Government's Research and Development (R&D) Tax Incentive scheme is anticipated to be received in December 2019.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to report statistically significant efficacy data from its in vivo mouse studies and further positive in vitro proof of concept data for its Gastrointestinal ReProgramming (GaRP) product.
Anatara Lifesciences Ltd's (ASX:ANR) lead human health product, GaRP, is being developed to specifically target two human gastrointestinal (GI) disorders, Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS), where there is a significant unmet medical need.
Cann Global Ltd (ASX:CGB) ("CGB" or "the Company") presents the annual report on activities for the year ending 30 June 2019.
MMJ Group Holdings Limited (ASX:MMJ) (FRA:2P9) (OTCMKTS:MMJJF), an Australian-listed company that specialises in managing a portfolio of investments along the cannabis value-chain, has invested CAD6m in the Canadian-listed company WeedMD Inc.
MMJ Group Holdings Limited (ASX:MMJ) (FRA:2P9) (OTCMKTS:MMJJF) cemented its place as the only Australian listed company that specialises in managing a portfolio of investments along the cannabis value-chain.